B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice

Journal of Immunology

Volumn 186, Issue 8, 2011, Pages 4984-4993

  Jacob, Noam ^a   Guo, Shunhua ^a   Mathian, Alexis ^b   Koss, Michael N ^a   Gindea, Simona ^c   Putterman, Chaim ^c   Jacob, Chaim O ^a   Stohl, William ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; B CELL ACTIVATING FACTOR; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN DEPOSITION; IMMUNOPATHOGENESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MEMORY T LYMPHOCYTE; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; NZM 2328 MOUSE; PLASMA CELL; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALS; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; FEMALE; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; KIDNEY; KIDNEY GLOMERULUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; MALE; MICE; MICE, INBRED NZB; MICE, INBRED STRAINS; MICE, KNOCKOUT; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES; TIME FACTORS;

EID: 79955022819     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000466     Document Type: Article

References (75)

1. Strasser, A., S. Whittingham, D. L. Vaux, M. L. Bath, J. M. Adams, S. Cory, and A. W. Harris. 1991. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. USA 88:8661-8665. (Pubitemid 21915417)
2. Botto, M., C. Dell'Agnola, A. E. Bygrave, E. M. Thompson, H. T. Cook, F. Petry, M. Loos, P. P. Pandolfi, and M. J. Walport. 1998. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19:56-59. (Pubitemid 28242023)
3. Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-151. (Pubitemid 29428807)
4. +/- mice. Science 285:2122-2125. (Pubitemid 29451429)
5. Bolland, S., and J. V. Ravetch. 2000. Spontaneous autoimmune disease in Fc (γ) RIIB-deficient mice results from strain-specific epistasis. Immunity 13:277-285.
6. Seshasayee, D., P. Valdez, M. Yan, V. M. Dixit, D. Tumas, and I. S. Grewal. 2003. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18:279-288. (Pubitemid 36263002)
7. Jacob, C. O., A. Reiff, D. L. Armstrong, B. L. Myones, E. Silverman, M. Klein-Gitelman, D. McCurdy, L. Wagner-Weiner, J. J. Nocton, A. Solomon, and R. Zidovetzki. 2007. Identification of novel susceptibility genes in childhoodonset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum. 56:4164-4173. (Pubitemid 350262344)
8. Remmers, E. F., R. M. Plenge, A. T. Lee, R. R. Graham, G. Hom, T. W. Behrens, P. I. W. de Bakker, J. M. Le, H.-S. Lee, F. Batliwalla, et al. 2007. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357:977-986. (Pubitemid 47367077)
9. Hom, G., R. R. Graham, B. Modrek, K. E. Taylor, W. Ortmann, S. Garnier, A. T. Lee, S. A. Chung, R. C. Ferreira, P. V. K. Pant, et al. 2008. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 358:900-909. (Pubitemid 351397089)
10. Harley, J. B., M. E. Alarcón-Riquelme, L. A. Criswell, C. O. Jacob, R. P. Kimberly, K. L. Moser, B. P. Tsao, T. J. Vyse, C. D. Langefeld, S. K. Nath, et al; International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN). 2008. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40:204-210. (Pubitemid 351171405)
11. Han, S., X. Kim-Howard, H. Deshmukh, Y. Kamatani, P. Viswanathan, J. M. Guthridge, K. Thomas, K. M. Kaufman, J. Ojwang, A. Rojas-Villarraga, et al. 2009. Evaluation of imputation-based association in and around the integrin-α-M (ITGAM) gene and replication of robust association between a nonsynonymous functional variant within ITGAM and systemic lupus erythematosus (SLE). Hum. Mol. Genet. 18:1171-1180.
12. Jacob, C. O., J. Zhu, D. L. Armstrong, M. Yan, J. Han, X. J. Zhou, J. A. Thomas, A. Reiff, B. L. Myones, J. O. Ojwang, et al. 2009. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 106:6256-6261.
13. Armstrong, D. L., A. Reiff, B. L. Myones, F. P. Quismorio, Jr., M. Klein-Gitelman, D. McCurdy, L. Wagner-Weiner, E. Silverman, J. O. Ojwang, K. M. Kaufman, et al. 2009. Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun. 10:446-456.
14. Webb, R., J. T. Merrill, J. A. Kelly, A. Sestak, K. M. Kaufman, C. D. Langefeld, J. Ziegler, R. P. Kimberly, J. C. Edberg, R. Ramsey-Goldman, et al. 2009. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum. 60:2402-2407.
15. Baechler, E. C., F. M. Batliwalla, G. Karypis, P. M. Gaffney, W. A. Ortmann, K. J. Espe, K. B. Shark, W. J. Grande, K. M. Hughes, V. Kapur, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100:2610-2615. (Pubitemid 36297546)
16. Bennett, L., A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, and V. Pascual. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711-723. (Pubitemid 36350866)
17. Kirou, K. A., C. Lee, S. George, K. Louca, I. G. Papagiannis, M. G. E. Peterson, N. Ly, R. N. Woodward, K. E. Fry, A. Y.-H. Lau, et al. 2004. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50:3958-3967. (Pubitemid 39643944)
18. Niewold, T. B., and W. I. Swedler. 2005. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin. Rheumatol. 24:178-181. (Pubitemid 40552976)
19. Kariuki, S. N., K. A. Kirou, E. J. MacDermott, L. Barillas-Arias, M. K. Crow, and T. B. Niewold. 2009. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-α in lupus patients in vivo. J. Immunol. 182:34-38.
20. Santiago-Raber, M.-L., R. Baccala, K. M. Haraldsson, D. Choubey, T. A. Stewart, D. H. Kono, and A. N. Theofilopoulos. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197:777-788. (Pubitemid 36350872)
21. Nacionales, D. C., K. M. Kelly-Scumpia, P. Y. Lee, J. S. Weinstein, R. Lyons, E. Sobel, M. Satoh, and W. H. Reeves. 2007. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56:3770-3783. (Pubitemid 350100710)
22. Agrawal, H., N. Jacob, E. Carreras, S. Bajana, C. Putterman, S. Turner, B. Neas, A. Mathian, M. N. Koss, W. Stohl, et al. 2009. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J. Immunol. 183:6021-6029.
23. 1 but not in BALB/c mice. J. Immunol. 174:2499-2506. (Pubitemid 40279662)
24. Shlomchik, M. J., M. P. Madaio, D. Ni, M. Trounstein, and D. Huszar. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180:1295-1306. (Pubitemid 24289603)
25. Chan, O. T. M., L. G. Hannum, A. M. Haberman, M. P. Madaio, and M. J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189:1639-1648.
26. Leandro, M. J., J. C. Edwards, G. Cambridge, M. R. Ehrenstein, and D. A. Isenberg. 2002. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46:2673-2677. (Pubitemid 36118931)
27. Looney, R. J., J. H. Anolik, D. Campbell, R. E. Felgar, F. Young, L. J. Arend, J. A. Sloand, J. Rosenblatt, and I. Sanz. 2004. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50:2580-2589. (Pubitemid 39062719)
28. Sfikakis, P. P., J. N. Boletis, S. Lionaki, V. Vigklis, K. G. Fragiadaki, A. Iniotaki, and H. M. Moutsopoulos. 2005. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52:501-513. (Pubitemid 40216314)
29. Gunnarsson, I., B. Sundelin, T. Jónsdóttir, S. H. Jacobson, E. W. Henriksson, and R. F. van Vollenhoven. 2007. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56:1263-1272. (Pubitemid 46608651)
30. Jónsdóttir, T., I. Gunnarsson, A. Risselada, E. W. Henriksson, L. Klareskog, and R. F. van Vollenhoven. 2008. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann. Rheum. Dis. 67:330-334. (Pubitemid 351281266)
31. Albert, D., J. Dunham, S. Khan, J. Stansberry, S. Kolasinski, D. Tsai, S. Pullman-Mooar, F. Barnack, C. Striebich, R. J. Looney, et al. 2008. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann. Rheum. Dis. 67:1724-1731.
32. Mackay, F., S. A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp, and J. L. Browning. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190:1697-1710. (Pubitemid 30002351)
33. Khare, S. D., I. Sarosi, X.-Z. Xia, S. McCabe, K. Miner, I. Solovyev, N. Hawkins, M. Kelley, D. Chang, G. Van, et al. 2000. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA 97:3370-3375. (Pubitemid 30183309)
34. Gross, J. A., J. Johnston, S. Mudri, R. Enselman, S. R. Dillon, K. Madden, W. Xu, J. Parrish-Novak, D. Foster, C. Lofton-Day, et al. 2000. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-999. (Pubitemid 30243593)
35. Stohl, W., D. Xu, K. S. Kim, M. N. Koss, T. N. Jorgensen, B. Deocharan, T. E. Metzger, S. A. Bixler, Y. S. Hong, C. M. Ambrose, et al. 2005. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 52:2080-2091. (Pubitemid 40994331)
36. Groom, J. R., C. A. Fletcher, S. N. Walters, S. T. Grey, S. V. Watt, M. J. Sweet, M. J. Smyth, C. R. Mackay, and F. Mackay. 2007. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204:1959-1971. (Pubitemid 47236330)
37. Kayagaki, N., M. Yan, D. Seshasayee, H. Wang, W. Lee, D. M. French, I. S. Grewal, A. G. Cochran, N. C. Gordon, J. Yin, et al. 2002. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17:515-524. (Pubitemid 35223539)
38. Ramanujam, M., X. Wang, W. Huang, L. Schiffer, C. Grimaldi, A. Akkerman, B. Diamond, M. P. Madaio, and A. Davidson. 2004. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. 173:3524-3534. (Pubitemid 39142063)
39. Ramanujam, M., X. Wang, W. Huang, Z. Liu, L. Schiffer, H. Tao, D. Frank, J. Rice, B. Diamond, K. O. A. Yu, et al. 2006. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J. Clin. Invest. 116:724-734. (Pubitemid 43326881)
40. Rudofsky, U. H., B. D. Evans, S. L. Balaban, V. D. Mottironi, and A. E. Gabrielsen. 1993. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab. Invest. 68:419-426. (Pubitemid 23136162)
41. Jacob, C. O., L. Pricop, C. Putterman, M. N. Koss, Y. Liu, M. Kollaros, S. A. Bixler, C. M. Ambrose, M. L. Scott, and W. Stohl. 2006. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J. Immunol. 177:2671-2680. (Pubitemid 44201026)
42. Wallace, D. J., W. Stohl, R. A. Furie, J. R. Lisse, J. D. McKay, J. T. Merrill, M. A. Petri, E. M. Ginzler, W. W. Chatham, W. J. McCune, et al. 2009. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61:1168-1178.
43. Furie, R. A., M. A. Petri, D. J. Wallace, E. M. Ginzler, J. T. Merrill, W. Stohl, W. W. Chatham, V. Strand, A. Weinstein, M. R. Chevrier, et al. 2009. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61:1143-1151.
44. Navarra, S., R. Guzman, A. Gallacher, R. A. Levy, E. K. Li, M. Thomas, R. Jimenez, M. Leon, S. Hall, J. L. Lan, et al; BLISS-52 Study Group. 2009. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. American College of Rheumatology 2009 Annual Scientific Meeting; Philadelphia, PA; October 17-21, 2009.
45. Furie, R., O. Zamani, D. Wallace, D. Tegzova, M. Petri, J. T. Merrill, W. Chatham, W. Stohl, A. Schwarting, S. Cooper, et al; BLISS-76 Study Group. 2010. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through wk 76. American College of Rheumatology 2010 Annual Scientific Meeting; Atlanta, GA; November 6-11, 2010.
46. Manzi, S., J. Sanchez-Guerrero, J. T. Merrill, R. A. Furie, D. Gladman, S. Navarra, E. M. Ginzler, D. D'Cruz, A. Doria, S. Cooper, et al; BLISS-52 and-76 Study Groups. 2010. Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and-76 studies. American College of Rheumatology 2010 Annual Scientific Meeting; Atlanta, GA; November 6-11, 2010.
47. Litinskiy, M. B., B. Nardelli, D. M. Hilbert, B. He, A. Schaffer, P. Casali, and A. Cerutti. 2002. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3:822-829.
48. Yao, Y., L. Richman, B. W. Higgs, C. A. Morehouse, M. de los Reyes, P. Brohawn, J. Zhang, B. White, A. J. Coyle, P. A. Kiener, and B. Jallal. 2009. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60:1785-1796.
49. Jacob, N., H. Yang, L. Pricop, Y. Liu, X. Gao, S. G. Zheng, J. Wang, H.-X. Gao, C. Putterman, M. N. Koss, et al. 2009. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J. Immunol. 182:2532-2541.
50. Morel, L., Y. Yu, K. R. Blenman, R. A. Caldwell, and E. K. Wakeland. 1996. Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm. Genome 7:335-339. (Pubitemid 126426665)
51. Markel, P., P. Shu, C. Ebeling, G. A. Carlson, D. L. Nagle, J. S. Smutko, and K. J. Moore. 1997. Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains. Nat. Genet. 17:280-284. (Pubitemid 27475989)
52. Waters, S. T., S. M. Fu, F. Gaskin, U. S. Deshmukh, S.-S. J. Sung, C. C. Kannapell, K. S. K. Tung, S. B. McEwen, and M. McDuffie. 2001. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin. Immunol. 100:372-383.
53. Deocharan, B., P. Marambio, M. Edelman, and C. Putterman. 2003. Differential effects of interleukin-4 in peptide induced autoimmunity. Clin. Immunol. 108:80-88. (Pubitemid 36960069)
54. Zhao, Z., L. C. Burkly, S. Campbell, N. Schwartz, A. Molano, A. Choudhury, R. A. Eisenberg, J. S. Michaelson, and C. Putterman. 2007. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J. Immunol. 179:7949-7958.
55. Jacob, C. O., S. Zang, L. Li, V. Ciobanu, F. Quismorio, A. Mizutani, M. Satoh, and M. Koss. 2003. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J. Immunol. 171:1564-1571. (Pubitemid 36900092)
56. Schiffer, L., R. Bethunaickan, M. Ramanujam, W. Huang, M. Schiffer, H. Tao, M. P. Madaio, E. P. Bottinger, and A. Davidson. 2008. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. [Published erratum appears in 2008 J. Immunol. 180:3613.] J. Immunol. 180:1938-1947.
57. Hron, J. D., and S. L. Peng. 2004. Type I IFN protects against murine lupus. J. Immunol. 173:2134-2142. (Pubitemid 38971652)
58. Fairhurst, A.-M., A. Mathian, J. E. Connolly, A. Wang, H. F. Gray, T. A. George, C. D. Boudreaux, X. J. Zhou, Q.-Z. Li, S. Koutouzov, et al. 2008. Systemic IFN-a drives kidney nephritis in B6. Sle123 mice. Eur. J. Immunol. 38:1948-1960.
59. Bekeredjian-Ding, I. B., M. Wagner, V. Hornung, T. Giese, M. Schnurr, S. Endres, and G. Hartmann. 2005. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. [Published erratum appears in 2005 J. Immunol. 174:5884.] J. Immunol. 174:4043-4050. (Pubitemid 40395980)
60. Ng, L. G., C.-H. Ng, B. Woehl, A. P. R. Sutherland, J. Huo, S. Xu, F. Mackay, and K.-P. Lam. 2006. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur. J. Immunol. 36:1837-1846. (Pubitemid 44089050)
61. Brummel, R., T. L. Roberts, K. J. Stacey, and P. Lenert. 2006. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice. Eur. J. Immunol. 36:1951-1962. (Pubitemid 44089060)
62. Treml, L. S., G. Carlesso, K. L. Hoek, J. E. Stadanlick, T. Kambayashi, R. J. Bram, M. P. Cancro, and W. N. Khan. 2007. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J. Immunol. 178:7531-7539. (Pubitemid 46898021)
63. Thibault, D. L., K. L. Graham, L. Y. Lee, I. Balboni, P. J. Hertzog, and P. J. Utz. 2009. Type I interferon receptor controls B-cell expression of nucleic acidsensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res. Ther. 11: R112.
64. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
65. Sadanaga, A., H. Nakashima, M. Akahoshi, K. Masutani, K. Miyake, T. Igawa, N. Sugiyama, H. Niiro, and M. Harada. 2007. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum. 56:1618-1628. (Pubitemid 46764091)
66. Yi, A. K., D. M. Klinman, T. L. Martin, S. Matson, and A. M. Krieg. 1996. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J. Immunol. 157:5394-5402. (Pubitemid 126448958)
67. Ryffel, B., B. D. Car, H. Gunn, D. Roman, P. Hiestand, and M. J. Mihatsch. 1994. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW) F1 mice. Am. J. Pathol. 144:927-937.
68. 1 mice. J. Clin. Invest. 94:585-591. (Pubitemid 24250987)
69. 1 mice. Clin. Exp. Immunol. 112:397-402. (Pubitemid 28267419)
70. Santini, S. M., C. Lapenta, M. Logozzi, S. Parlato, M. Spada, T. Di Pucchio, and F. Belardelli. 2000. Type I interferon as a powerful adjuvant for monocytederived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191:1777-1788. (Pubitemid 30331574)
71. Blanco, P., A. K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294:1540-1543. (Pubitemid 33063928)
72. Nardelli, B., O. Belvedere, V. Roschke, P. A. Moore, H. S. Olsen, T. S. Migone, S. Sosnovtseva, J. A. Carrell, P. Feng, J. G. Giri, and D. M. Hilbert. 2001. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97:198-204. (Pubitemid 32061261)
73. Chang, S. K., S. A. Mihalcik, and D. F. Jelinek. 2008. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J. Immunol. 180:7394-7403.
74. Lai Kwan Lam, Q., O. King Hung Ko, B. J. Zheng, and L. Lu. 2008. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc. Natl. Acad. Sci. USA 105:14993-14998.
75. 1) mice mimics some but not all features associated with the Ya a mutation. Arthritis Rheum. 60:1096-1101.